Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hideto Ueki

Showing results (21-30 of 47) with videos related to

Pageof 5
Sort By:
International Cancer Conference Journal|December 15, 2025
Pathologic complete response to enfortumab vedotin plus pembrolizumab in node-positive urothelial carcinoma: a case reportTakuto Hara, Eiki Inoue, Naoto Wakita, et al.
Japanese Journal of Clinical Oncology|February 24, 2023
Treatment outcome after sequential chemotherapy with cisplatin-etoposide, amrubicin and nogitecan in patients with treatment-related pure small-cell neuroendocrine prostate cancerHideto Ueki, Tomoaki Terakawa, Takuto Hara, et al.
Anticancer Research|March 4, 2025
Genomic Profiling of Small Cell Neuroendocrine Prostate Cancer and its Implications for Targeted TherapiesJunichiro Hirata, Takuto Hara, Naoe Jimbo, et al.
BMC Cancer|February 5, 2025
Safety and efficacy of oral cancer vaccine B440 in patients with PD-1/PD-L1 inhibitor-resistant advanced urothelial cancer: a study protocol for a phase 1 multicenter, open-label, single-arm clinical trialJunya Furukawa, Yasumasa Kakei, Sae Murakami, et al.
The Prostate|January 18, 2026
Prognostic Impact of Initial Prostate Specific Antigen Half-Life After Abiraterone Acetate in High-Volume Metastatic Hormone-Sensitive Prostate Cancer: Who May Need Triplet Therapy?Kotaro Suzuki, Hideto Ueki, Naoto Wakita, et al.
Urologic Oncology|April 4, 2026
Adequate Bacillus Calmette-Guérin maintenance therapy improves recurrence-free survival in high-risk non-muscle-invasive bladder cancer: A conditional survival studyYukari Bando, Jun Teishima, Taisuke Tobe, et al.
Cancers|December 17, 2024
Utility of Machine Learning Models to Predict Lymph Node Metastasis of Japanese Localized Prostate CancerHideto Ueki, Tomoaki Terakawa, Takuto Hara, et al.
Urologic Oncology|November 13, 2024
Impact of neoadjuvant therapy on prognosis in renal cell carcinoma with inferior vena cava thrombusTakuto Hara, Kotaro Suzuki, Yasuyoshi Okamura, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|April 7, 2025
Prognostic Impact of the Maximal Evaluable Lesion Size in Patients With Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab Combination TherapyYoshie Mita, Jun Teishima, Takuto Hara, et al.
Japanese Journal of Clinical Oncology|February 11, 2026
Risk stratification by pathological upstaging and tumor necrosis in clinical T1 clear-cell renal cell carcinoma: evidence from a multi-institutional cohort of 1081 patientsHideto Ueki, Takuto Hara, Taisuke Tobe, et al.
Pageof 5

Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
International Cancer Conference Journal|December 15, 2025
Pathologic complete response to enfortumab vedotin plus pembrolizumab in node-positive urothelial carcinoma: a case reportTakuto Hara, Eiki Inoue, Naoto Wakita, et al.
Japanese Journal of Clinical Oncology|February 24, 2023
Treatment outcome after sequential chemotherapy with cisplatin-etoposide, amrubicin and nogitecan in patients with treatment-related pure small-cell neuroendocrine prostate cancerHideto Ueki, Tomoaki Terakawa, Takuto Hara, et al.
Anticancer Research|March 4, 2025
Genomic Profiling of Small Cell Neuroendocrine Prostate Cancer and its Implications for Targeted TherapiesJunichiro Hirata, Takuto Hara, Naoe Jimbo, et al.
BMC Cancer|February 5, 2025
Safety and efficacy of oral cancer vaccine B440 in patients with PD-1/PD-L1 inhibitor-resistant advanced urothelial cancer: a study protocol for a phase 1 multicenter, open-label, single-arm clinical trialJunya Furukawa, Yasumasa Kakei, Sae Murakami, et al.
The Prostate|January 18, 2026
Prognostic Impact of Initial Prostate Specific Antigen Half-Life After Abiraterone Acetate in High-Volume Metastatic Hormone-Sensitive Prostate Cancer: Who May Need Triplet Therapy?Kotaro Suzuki, Hideto Ueki, Naoto Wakita, et al.
Urologic Oncology|April 4, 2026
Adequate Bacillus Calmette-Guérin maintenance therapy improves recurrence-free survival in high-risk non-muscle-invasive bladder cancer: A conditional survival studyYukari Bando, Jun Teishima, Taisuke Tobe, et al.
Cancers|December 17, 2024
Utility of Machine Learning Models to Predict Lymph Node Metastasis of Japanese Localized Prostate CancerHideto Ueki, Tomoaki Terakawa, Takuto Hara, et al.
Urologic Oncology|November 13, 2024
Impact of neoadjuvant therapy on prognosis in renal cell carcinoma with inferior vena cava thrombusTakuto Hara, Kotaro Suzuki, Yasuyoshi Okamura, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|April 7, 2025
Prognostic Impact of the Maximal Evaluable Lesion Size in Patients With Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab Combination TherapyYoshie Mita, Jun Teishima, Takuto Hara, et al.
Japanese Journal of Clinical Oncology|February 11, 2026
Risk stratification by pathological upstaging and tumor necrosis in clinical T1 clear-cell renal cell carcinoma: evidence from a multi-institutional cohort of 1081 patientsHideto Ueki, Takuto Hara, Taisuke Tobe, et al.
Pageof 5